Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B

VERTEX PHARMACEUTICALS INC / MA

2023-Q2 EPS reported $6.21 revenue$4,868,000,000

Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).
Full-year CF product revenue guidance raised to $9.7-$9.8B from $9.55-$9.7B; R&D/SG&A guidance also raised.
FDA accepted exa-cel BLAs for SCD & TDT; Priority Review for SCD, PDUFA Dec 8, 2023; TDT PDUFA Mar 30, 2024.
Vanzacaftor triple SKYLINE & RIDGELINE studies expected to complete by end of 2023; results in early 2024.
VX-548 pivotal program in acute pain expected to complete late 2023; results late 2023/early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERTEX PHARMACEUTICALS INC / MA reported the second quarter ended June 30, 2023 results: revenue $2.49 billion. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $2.49 billion
Guidance: raised
Result: reported results

Exact text from the filing

Vertex Reports Second Quarter 2023 Financial Results — Product revenue of $2.49 billion

View on SEC.gov

2 earnings releases filed in the last 30 days. Browse all earnings releases →

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.